Dabigatran etexilate - VTE prevention post hip/knee replacement
You are here : Home > Formulary Search > Dabigatran etexilate - VTE prevention post hip/knee replacement
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Dabigatran etexilate
Indication :
VTE prevention post hip/knee replacement
Group Name :
Keywords :
NOAC, anticoagulant cards, anticoagulant alert cards
Brand Names Include :
Pradaxa
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Other Indications
Below are listed other indications that Dabigatran etexilate is used to treat.
Other Drugs
Below are listed other drugs that are used to treat VTE prevention post hip/knee replacement.
Committee Recommendations (2)
01 Jun 16 -
Surrey Medicines Commissioners Group
Surrey Medicines Commissioning Group recommend that patients prescribed all types of anticoagulants (warfarin and NOACs) should be given an anticoagulant alert card to carry with them. For patients taking NOACs, the card should be annotated on the reverse in the “Therapeutic range (INR)” box with the words “not applicable” or “not required for this drug”.
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The committee confirmed that dabigatran should be considered a hospital only RED drug for the prevention of venous thromboembolism after total hip or total knee replacement in adults